Prevalence of metabolic syndrome and its association with depression in patients with schizophrenia

Neuropsychiatric Disease and Treatment

Volumn 9, Issue , 2013, Pages 941-946

  Suttajit, Sirijit ^a   Pilakanta, Sutrak ^a  

^a CHIANG MAI UNIVERSITY   (Thailand)

Author keywords

Central obesity; Dyslipidemia; Hyperglycemia; Hypertension; Mood symptoms

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; ARTICLE; CENTRAL OBESITY; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE DURATION; DISEASE PREDISPOSITION; FEMALE; FOLLOW UP; HAMILTON SCALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MENTAL DEFICIENCY; METABOLIC SYNDROME X; OBESITY; PREVALENCE; SCHIZOPHRENIA; SEPARATED PERSON; SYMPTOM; WAIST CIRCUMFERENCE; WIDOWED PERSON;

EID: 84880100617     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S47450     Document Type: Article

References (36)

1. Laursen TM, Munk-Olsen T, Vestergaard M. Life expectancy and cardiovascular mortality in persons with schizophrenia. Curr Opin Psychiatry. 2012;25(2):83-88.
2. Hayes RD, Chang CK, Fernandes A, et al. Associations between symptoms and all-cause mortality in individuals with serious mental illness. J Psychosom Res. 2012;72(2):114-119.
3. Osby U, Correia N, Brandt L, Ekbom A, Sparen P. Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr Res. 2000;45(1-2):21-28.
4. Joukamaa M, Heliovaara M, Knekt P, Aromaa A, Raitasalo R, Lehtinen V. Schizophrenia, neuroleptic medication and mortality. Br J Psychiatry. 2006;188:122-127.
5. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome - a new worldwide defnition. Lancet. 2005;366(9491):1059-1062.
6. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112(17):2735-2752.
7. Boyko EJ, de Courten M, Zimmet PZ, Chitson P, Tuomilehto J, Alberti KG. Features of the metabolic syndrome predict higher risk of diabetes and impaired glucose tolerance: a prospective study in Mauritius. Diabetes Care. 2000;23(9):1242-1248.
8. Hu G, Qiao Q, Tuomilehto J, Eliasson M, Feskens EJ, Pyorala K. Plasma insulin and cardiovascular mortality in non-diabetic European men and women: a meta-analysis of data from eleven prospective studies. Diabetologia. 2004;47(7):1245-1256.
9. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001;414(6865):782-787.
10. Carey VJ, Walters EE, Colditz GA, et al. Body fat distribution and risk of non-insulin-dependent diabetes mellitus in women. The Nurses' Health Study. Am J Epidemiol. 1997;145(7):614-619.
11. Hausswolff-Juhlin Y, Bjartveit M, Lindstrom E, Jones P. Schizophrenia and physical health problems. Acta Psychiatr Scand Suppl. 2009;(438):15-21.
12. Lee CM, Huxley RR, Woodward M, et al. The metabolic syndrome identifes a heterogeneous group of metabolic component combinations in the Asia-Pacific region. Diabetes Res Clin Pract. 2008;81(3): 377-380.
13. Lee CM, Huxley RR, Woodward M, et al. Comparisons of metabolic syndrome defnitions in four populations of the Asia-Pacific region. Metab Syndr Relat Disord. 2008;6(1):37-46.
14. Udomratn P. Metabolic syndrome in psychiatric patients treated with antipsychotic drugs in Thailand. Clinical Psychopharmacology and Neuroscience. 2010;8(2):79-83.
15. Kassi E, Pervanidou P, Kaltsas G, Chrousos G. Metabolic syndrome: defnitions and controversies. BMC Med. 2011; 9: 48: 1-13.
16. Hasnain M, Vieweg W V, Fredrickson SK, Beatty-Brooks M, Fernandez A, Pandurangi AK. Clinical monitoring and management of the metabolic syndrome in patients receiving atypical antipsychotic medications. Prim Care Diabetes. 2009;3(1):5-15.
17. Suttajit S, Pilakanta, S. Prevalence of and factors associated with depression in patients with schizophrenia in Thailand: a post-hoc analysis. Chiang Mai Medical Journal. 2011;50(4):115-121.
18. Thakore JH. Metabolic syndrome and schizophrenia. Br J Psychiatry. 2005;186:455-456.
19. East C, Willis BL, Barlow CE, et al. Depressive symptoms and m e tabolic syndrome in preventive healthcare: the Cooper Center longitudinal study. Metab Syndr Relat Disord. 2010;8(5):451-457.
20. Srisurapanont M, Likhitsathian S, Boonyanaruthee V, Charnsilp C, Jarusuraisin N. Metabolic syndrome in Thai schizophrenic patients: a naturalistic one-year follow-up study. BMC Psychiatry. 2007;7:14.
21. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. (Test Revision.) Washington, DC: American Psychiatric Association; 2000.
22. McEvoy J P, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 2005;80(1):19-32.
23. Mitchell AJ, Vancampfort D, Sweers K, van Winkel R, Yu W, De Hert M. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders - a systematic review and meta-analysis. Schizophr Bull. 2013;39(2):306-318.
24. Nestel P, Lyu R, Low L P, et al. Metabolic syndrome: recent prevalence in East and Southeast Asian populations. Asia Pac J Clin Nutr. 2007;16(2):362-367.
25. Meyer JM, Nasrallah HA, McEvoy J P, et al. The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome. Schizophr Res. 2005;80(1):9-18.
26. Akbaraly TN, Kivimaki M, Brunner EJ, et al. Association between metabolic syndrome and depressive symptoms in middle-aged adults: results from the Whitehall II study. Diabetes Care. 2009;32(3):499-504.
27. Viinamaki H, Heiskanen T, Lehto SM, et al. Association of depressive symptoms and metabolic syndrome in men. Acta Psychiatr Scand. 2009;120(1):23-29.
28. Holsboer F. Stress, hypercortisolism and corticosteroid receptors in depression: implications for therapy. J Affect Disord. 2001;62(1-2): 77-91.
29. Rosmond R, Bjorntorp P. The hypothalamic-pituitary-adrenal axis activity as a predictor of cardiovascular disease, type 2 diabetes and stroke. J Intern Med. 2000;247(2):188-197.
30. Toalson P, Ahmed S, Hardy T, Kabinoff G. The metabolic syndrome in patients with severe mental illnesses. Prim Care Companion J Clin Psychiatry. 2004;6(4):152-158.
31. Gardner DM, Baldessarini RJ, Waraich P. Modern antipsychotic drugs: a critical overview. CMAJ. 2005;172(13):1703-1711.
32. Ross CE. Overweight and depression. J Health Soc Behav. 1994; 35(1):63-79.
33. Perlis ML, Smith LJ, Lyness JM, et al. Insomnia as a risk factor for onset of depression in the elderly. Behav Sleep Med. 2006;4(2):104-113.
34. Bjornsdottir E, Janson C, Gislason T, et al. Insomnia in untreated sleep apnea patients compared to controls. J Sleep Res. 2012;21(2): 131-138.
35. Hu G, Qiao Q, Tuomilehto J, Balkau B, Borch-Johnsen K, Pyorala K. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med. 2004;164(10):1066-1076.
36. Ban HJ, Kim SC, Seo J, Kang HB, Choi JK. Genetic and metabolic characterization of insomnia. PLoS One. 2011;6(4):e18455.